Hepatitis B vaccine - Bavarian Nordic

Drug Profile

Hepatitis B vaccine - Bavarian Nordic

Alternative Names: HBV vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic HBV vaccine; MVA-BN HBV vaccine; MVA-BN Hepatitis B vaccine - Bavarian Nordic

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic
  • Developer Janssen
  • Class Hepatitis B vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 29 Sep 2017 Preclinical trials in Hepatitis B in USA (Parenteral) before September 2017 (Bavarian Nordic pipeline, September 2017)
  • 27 Jul 2017 Bavarian Nordic and Janssen expand their collaboration to develop vaccines for human immunodeficiency virus (HIV-1) and hepatitis B infections
  • 27 Jul 2017 Hepatitis B vaccine licensed to Janssen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top